Cabe after the successful completion of phase i would expect a...

Cabe after the successful completion of phase i would expect a market cap of at least 50 million which would give a sp of some 5 cents.This price would really show no moving forward value.
After commercialisation, well we know that many would possibly switch from the inferior Somavert so the following passage in the presentation comes in to play.Potentially a market cap in this instant for ANP of who knows as the future potential needs to be taken into account but i would expect to see ANP in this scenario trading near 70 cents minimum in my view.

"Target market for ATL1103 is at least the 35-40% of acromegalics who are not controlled on somatostatiins,in addition to those who would switch from Somavert?
because of therapy limitations = potential market opportunity of up to $500 mill/annum in acromegaly indication."

Robbbssstttarrrrrr